Contact
searchSearch
HMP Global

Breast Cancer Topic Center

Featured Article

Conference Coverage
Medicaid Expansion Linked to Early Breast Cancer Treatment, Survival Among Young Adult Women
06/02/2023
Hannah Musick
A new study showed Medicaid expansion in the United States was associated with increased receipt of timely, guideline-concordant breast cancer treatment and improved survival for young adult women.
A new study showed Medicaid expansion in the United States was associated with increased receipt of timely, guideline-concordant breast cancer treatment and improved survival for young adult women.
A new study showed Medicaid...
06/02/2023
First Report Managed Care
Conference Coverage
Breast Cancer Data Discrepancies Found Across National Tumor Registries
06/02/2023
Hannah Musick
Researchers at the 2023 ASCO Annual Meeting compared data on breast cancer cases in 3 national databases to identify differences in case coverage.
Researchers at the 2023 ASCO Annual Meeting compared data on breast cancer cases in 3 national databases to identify differences in case coverage.
Researchers at the 2023 ASCO...
06/02/2023
First Report Managed Care
News
Lower Incidence of Breast Cancer Among Female Veterans Deployed During Post-9/11 Conflicts
02/02/2023
Maria Asimopoulos
Using data from more than 500,000 women treated in Veterans Affairs facilities, researchers evaluated associations between breast cancer diagnoses and history of deployment.
Using data from more than 500,000 women treated in Veterans Affairs facilities, researchers evaluated associations between breast cancer diagnoses and history of deployment.
Using data from more than...
02/02/2023
Veterans Health Today
From Veterans Health Today
Conference Coverage
Black Women More Likely to Experience Dose Delays, Worse Outcomes in Triple-Negative Breast Cancer Treatment
06/10/2022
Maria Asimopoulos
Findings presented at the 2022 ASCO Annual Meeting suggest there are disparities in care for Black women with triple-negative breast cancer as compared with White women.
Findings presented at the 2022 ASCO Annual Meeting suggest there are disparities in care for Black women with triple-negative breast cancer as compared with White women.
Findings presented at the 2022...
06/10/2022
First Report Managed Care
Conference Coverage
Symptom-Related Quality of Life in Patients Treated With First-Line Ribociclib vs Ademaciclib
06/10/2022
Maria Asimopoulos
Investigators at the 2022 ASCO Annual Meeting compared symptoms in patients receiving either ribociclib or abemaciclib in combination with endocrine therapy in the front-line setting for HR+/HER2- advanced breast cancer.
Investigators at the 2022 ASCO Annual Meeting compared symptoms in patients receiving either ribociclib or abemaciclib in combination with endocrine therapy in the front-line setting for HR+/HER2- advanced breast cancer.
Investigators at the 2022 ASCO...
06/10/2022
First Report Managed Care
Conference Coverage
Treatment Costs, Care of Patients With Metastatic Breast Cancer in the United States
06/10/2022
Samantha Matthews
Costs related to metastatic breast cancer vary by receptor subtype as well as the number of years postdiagnosis, according to research presented at the 2022 ASCO Annual Meeting.
Costs related to metastatic breast cancer vary by receptor subtype as well as the number of years postdiagnosis, according to research presented at the 2022 ASCO Annual Meeting.
Costs related to metastatic...
06/10/2022
First Report Managed Care
Conference Coverage
Assessing Alpelisib, Fulvestrant Benefit Among Patients With Advanced Breast Cancer
06/07/2022
Samantha Matthews
“Clinical benefit was maintained regardless of alterations in most biomarkers, including ESR1 and genes implicated in CDK4/6i resistance, consistent with alpelisib targeting the PIK3CA driver oncogene,” wrote researchers.
“Clinical benefit was maintained regardless of alterations in most biomarkers, including ESR1 and genes implicated in CDK4/6i resistance, consistent with alpelisib targeting the PIK3CA driver oncogene,” wrote researchers.
“Clinical benefit was maintained...
06/07/2022
First Report Managed Care
Conference Coverage
Real-World Data Suggests Palbociclib Efficacious for Treating HR+/HER2- Advanced Breast Cancer
06/06/2022
Maria Asimopoulos
A multicenter study of real-world practices in China showed palbociclib plus endocrine therapy was efficacious among patients with HR+/HER2- advanced breast cancer.
A multicenter study of real-world practices in China showed palbociclib plus endocrine therapy was efficacious among patients with HR+/HER2- advanced breast cancer.
A multicenter study of...
06/06/2022
First Report Managed Care
Conference Coverage
Effect of Ribociclib Dose Modifications on Overall Survival in Patients With HR+/HER2- Advanced Breast Cancer
06/06/2022
Samantha Matthews
Researchers at the 2022 ASCO Annual Meeting shared promising results from a trial examining the effect of dosage modifications on overall survival among postmenopausal patients with HR+/HER2- advanced breast cancer.
Researchers at the 2022 ASCO Annual Meeting shared promising results from a trial examining the effect of dosage modifications on overall survival among postmenopausal patients with HR+/HER2- advanced breast cancer.
Researchers at the 2022 ASCO...
06/06/2022
First Report Managed Care
Icario logo
Commentary
New Research to Bridge Gaps in Care for Breast Cancer Amid COVID-19
09/01/2021
In this commentary, the Icario team showcases engagement strategies to bridge gaps in breast cancer care after the COVID-19 pandemic reduced number of screenings and exacerbated barriers to access.
In this commentary, the Icario team showcases engagement strategies to bridge gaps in breast cancer care after the COVID-19 pandemic reduced number of screenings and exacerbated barriers to access.
In this commentary, the Icario...
09/01/2021
First Report Managed Care
William Audeh, MD, MS
Videos
Genomic Risk Scoring Reduces Unnecessary Chemotherapy for Breast Cancer
06/11/2021
Julie Gould
William Audeh, MD, MS, chief medical officer for Agendia, discusses the results of the MINDACT study, including how genomic risk scoring in women with breast cancer could successfully prevent unnecessary chemotherapy treatment, as well as the...
William Audeh, MD, MS, chief medical officer for Agendia, discusses the results of the MINDACT study, including how genomic risk scoring in women with breast cancer could successfully prevent unnecessary chemotherapy treatment, as well as the...
William Audeh, MD, MS, chief...
06/11/2021
First Report Managed Care

Newsfeed

News
Lower Incidence of Breast Cancer Among Female Veterans Deployed During Post-9/11 Conflicts
02/02/2023
Maria Asimopoulos
Using data from more than 500,000 women treated in Veterans Affairs facilities, researchers evaluated associations between breast cancer diagnoses and history of deployment.
Using data from more than 500,000 women treated in Veterans Affairs facilities, researchers evaluated associations between breast cancer diagnoses and history of deployment.
Using data from more than...
02/02/2023
Veterans Health Today
News
Trump Administration Announces 17th Most-Favored-Nation Drug Pricing Agreement With Regeneron
04/23/2026
Danielle Sposato
The Trump Administration today announced a new agreement with pharmaceutical manufacturer Regeneron aimed at aligning US prescription drug prices with those paid in other developed nations under a most-favored-nation (MFN) pricing model.
The Trump Administration today announced a new agreement with pharmaceutical manufacturer Regeneron aimed at aligning US prescription drug prices with those paid in other developed nations under a most-favored-nation (MFN) pricing model.
The Trump Administration today...
04/23/2026
First Report Managed Care
News
Trump Administration Announces 17th Most-Favored-Nation Drug Pricing Agreement With Regeneron
04/23/2026
Danielle Sposato
The Trump Administration today announced a new agreement with pharmaceutical manufacturer Regeneron aimed at aligning US prescription drug prices with those paid in other developed nations under a most-favored-nation (MFN) pricing model.
The Trump Administration today announced a new agreement with pharmaceutical manufacturer Regeneron aimed at aligning US prescription drug prices with those paid in other developed nations under a most-favored-nation (MFN) pricing model.
The Trump Administration today...
04/23/2026
First Report Managed Care
News
Semaglutide Shows Health Benefits for CVD but Falls Short on Cost-Effectiveness at Current Drug Prices
04/23/2026
Rebecca Amrick
A simulation study found that semaglutide could deliver meaningful health benefits as a secondary prevention strategy for cardiovascular disease (CVD) but will only be cost-effective if current drug prices are reduced.
A simulation study found that semaglutide could deliver meaningful health benefits as a secondary prevention strategy for cardiovascular disease (CVD) but will only be cost-effective if current drug prices are reduced.
A simulation study found that...
04/23/2026
First Report Managed Care
Behind the Bill
DOJ Places FDA-Approved Marijuana Products in Schedule III
04/23/2026
Grace Taylor, MS, MA
The US Department of Justice (DOJ) has reclassified certain US Food and Drug Administration (FDA)-approved marijuana products as Schedule III substances, a shift that may expand research and influence future clinical and coverage decisions in...
The US Department of Justice (DOJ) has reclassified certain US Food and Drug Administration (FDA)-approved marijuana products as Schedule III substances, a shift that may expand research and influence future clinical and coverage decisions in...
The US Department of Justice...
04/23/2026
First Report Managed Care
News
Using One Bispecific Antibody to Treat R/R DLBCL and FL Can Potentially Reduce Staff Time and Care Costs
04/22/2026
Rebecca Amrick
A survey of 105 US professionals estimated the reduction in physician hours and care costs that would result from using epcoritamab to treat patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) and follicular...
A survey of 105 US professionals estimated the reduction in physician hours and care costs that would result from using epcoritamab to treat patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) and follicular...
A survey of 105 US professionals...
04/22/2026
First Report Managed Care
News
Outpatient Epcoritamab Dosing Feasible in R/R DLBCL, Study Finds
04/20/2026
Grace Taylor, MS, MA
According to a recent study, outpatient monitoring after epcoritamab initiation showed manageable safety and strong response rates in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), potentially reducing the need for routine...
According to a recent study, outpatient monitoring after epcoritamab initiation showed manageable safety and strong response rates in relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), potentially reducing the need for routine...
According to a recent study,...
04/20/2026
First Report Managed Care
News
Location Creates Travel Burden and Treatment Inequities for Patients With DLBCL and FL
04/17/2026
Rebecca Amrick
A study observed inequities in the time and distance it takes patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) to travel for treatment.
A study observed inequities in the time and distance it takes patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) to travel for treatment.
A study observed inequities in...
04/17/2026
First Report Managed Care
News
Real-World Elranatamab in RRMM Falls Short on Durability Despite Strong Initial Responses
04/17/2026
Rebecca Amrick
Elranatamab shows promising response rates in real-world relapsed or refractory multiple myeloma (RRMM), but shorter durability, prior B-cell maturation antigen (BCMA) exposure, and high infection risk raise questions about optimal patient...
Elranatamab shows promising response rates in real-world relapsed or refractory multiple myeloma (RRMM), but shorter durability, prior B-cell maturation antigen (BCMA) exposure, and high infection risk raise questions about optimal patient...
Elranatamab shows promising...
04/17/2026
First Report Managed Care
News
Real-World Data Show Semaglutide’s Impact on Health Care Utilization and Medical Costs for Patients With OW/OB
04/17/2026
Rebecca Amrick
A large observational study of a US administrative claims database examined the effects of semaglutide on health care resource utilization (HCRU) and medical costs in patients with overweight or obesity (OW/OB) and multimorbidity.
A large observational study of a US administrative claims database examined the effects of semaglutide on health care resource utilization (HCRU) and medical costs in patients with overweight or obesity (OW/OB) and multimorbidity.
A large observational study of a...
04/17/2026
First Report Managed Care
News
Improving RVU Compensation Models to be More Equitable for Transplant Nephrologists
04/16/2026
Rebecca Amrick
A comprehensive study outlines the main issues with current compensation models for transplant nephrologists and provides solutions to improving these models.
A comprehensive study outlines the main issues with current compensation models for transplant nephrologists and provides solutions to improving these models.
A comprehensive study outlines...
04/16/2026
First Report Managed Care

Insights

Icario logo
Commentary
New Research to Bridge Gaps in Care for Breast Cancer Amid COVID-19
09/01/2021
In this commentary, the Icario team showcases engagement strategies to bridge gaps in breast cancer care after the COVID-19 pandemic reduced number of screenings and exacerbated barriers to access.
In this commentary, the Icario team showcases engagement strategies to bridge gaps in breast cancer care after the COVID-19 pandemic reduced number of screenings and exacerbated barriers to access.
In this commentary, the Icario...
09/01/2021
First Report Managed Care
William Audeh, MD, MS
Videos
Genomic Risk Scoring Reduces Unnecessary Chemotherapy for Breast Cancer
06/11/2021
Julie Gould
William Audeh, MD, MS, chief medical officer for Agendia, discusses the results of the MINDACT study, including how genomic risk scoring in women with breast cancer could successfully prevent unnecessary chemotherapy treatment, as well as the...
William Audeh, MD, MS, chief medical officer for Agendia, discusses the results of the MINDACT study, including how genomic risk scoring in women with breast cancer could successfully prevent unnecessary chemotherapy treatment, as well as the...
William Audeh, MD, MS, chief...
06/11/2021
First Report Managed Care
Headshot of Dr Joanne Mortimer on a blue background underneath the PopHealth Perspectives logo.
Podcasts
Considering Patient Needs to Ensure Effective Treatments and Reduce Payer Costs
06/03/2021
Julie Gould
Joanne Mortimer, MD, director of women’s cancer programs at City of Hope, discusses the unique challenges of treating breast cancer, the importance of patient-centered treatment, and what payers can do to better accommodate patient needs...
Joanne Mortimer, MD, director of women’s cancer programs at City of Hope, discusses the unique challenges of treating breast cancer, the importance of patient-centered treatment, and what payers can do to better accommodate patient needs...
Joanne Mortimer, MD, director of...
06/03/2021
First Report Managed Care
Podcasts
The Critical Need for Continued Research in Breast Cancer
05/06/2021
Alison Conlin, MD, MPH, medical oncologist, Providence Cancer Institute, stresses the importance of research in breast cancer care and says the stressors and outcomes of the pandemic share similarity to those of a cancer-related outcomes.
Alison Conlin, MD, MPH, medical oncologist, Providence Cancer Institute, stresses the importance of research in breast cancer care and says the stressors and outcomes of the pandemic share similarity to those of a cancer-related outcomes.
Alison Conlin, MD, MPH, medical...
05/06/2021
First Report Managed Care
Podcasts
Common Treatment Challenges Among Patients With Breast Cancer and How it Compares to Other Cancer Types
02/19/2021
William Rayford Gwin III, MD, medical oncologist, Seattle Cancer Care Alliance, breaks down some common challenges in treating breast cancer that make it unique compared to other types of cancer, and provides some risk reducing strategies for...
William Rayford Gwin III, MD, medical oncologist, Seattle Cancer Care Alliance, breaks down some common challenges in treating breast cancer that make it unique compared to other types of cancer, and provides some risk reducing strategies for...
William Rayford Gwin III, MD,...
02/19/2021
First Report Managed Care
Podcasts
Navigating Through Breast Cancer Care With the Entire Care Team and Addressing Medication Costs
01/07/2021
Jairam Krishnamurthy, MD, FACP, assistant professor of medicine, University of Nebraska Medical Center, reviews what it is like to navigate through breast cancer care with the whole care team—including the patient, pharmacists, other...
Jairam Krishnamurthy, MD, FACP, assistant professor of medicine, University of Nebraska Medical Center, reviews what it is like to navigate through breast cancer care with the whole care team—including the patient, pharmacists, other...
Jairam Krishnamurthy, MD, FACP,...
01/07/2021
First Report Managed Care
Podcasts
Identifying Risk-Reducing Strategies for Breast Cancer and How Payers Can Address the Costs of Medications
12/09/2020
Victor G Vogel, MD, medical oncologist, Geisinger Health System, discusses a variety of risk reducing strategies for breast cancer, including why some are “overdue,” explains why there is a lack in the uptake of medications among patients...
Victor G Vogel, MD, medical oncologist, Geisinger Health System, discusses a variety of risk reducing strategies for breast cancer, including why some are “overdue,” explains why there is a lack in the uptake of medications among patients...
Victor G Vogel, MD, medical...
12/09/2020
First Report Managed Care

Interactive Features

Pipeline Projections

PIPELINE PROJECTIONS
Emerging Therapies Reshaping Atopic Dermatitis Care
03/26/2026
Roy Moore
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly expanding atopic dermatitis pipeline is intensifying competition, reshaping payer strategies, and raising the bar for new therapies.
Roy Moore outlines how a rapidly...
03/26/2026
First Report Managed Care
Pipe
Pipeline Projections
Emerging Migraine Treatments Challenge a Mature Market
11/20/2025
Roy Moore
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market access team discussed the evolving migraine treatment landscape, highlighting the maturation of the acute and prophylactic markets, the emergence of new therapies such as triptan-COX-2 combinations, gepants,...
Roy Moore of Clarivate’s market...
11/20/2025
First Report Managed Care
Pipeline Projections
Pipeline Projections
Redefining Asthma Management With Emerging Anti-Inflammatories
10/01/2025
Roy Moore
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access expert, discusses the evolving asthma drug pipeline, highlighting upcoming therapies—including Breztri, depemokimab, and masitinib—their potential to improve adherence and outcomes, payer considerations around cost...
Roy Moore, a market access...
10/01/2025
First Report Managed Care
Pipeline Projections
The Shift in MS Care as Biologics and BTK Inhibitors Advance
07/25/2025
Roy Moore
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline Projections, Roy Moore breaks down the rapidly evolving landscape of multiple sclerosis treatments—highlighting the shift from injectables to orals, the rise of monoclonal antibodies, and the promise of innovative...
In this edition of Pipeline...
07/25/2025
First Report Managed Care
Pipeline Projections
How Biosimilars Are Shaping RA Treatment and Reimbursement Strategies
04/29/2025
Roy Moore
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline Projections, Roy Moore—Senior Healthcare Research & Data Analyst at Clarivate—discusses the expanding biosimilar pipeline for autoimmune diseases. He highlights recent FDA approvals, formulary and pricing...
In this episode of Pipeline...
04/29/2025
First Report Managed Care

Behind the Bill

Behind the Bill
HHS Hits Reset on 340B Rebate Model After Court Setbacks
02/11/2026
Juliet Gallagher
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and Human Services (HHS) has formally scrapped its 340B Rebate Model Pilot Program following a series of court rulings that blocked its implementation—signaling a significant pause in one of the most closely...
The US Department of Health and...
02/11/2026
First Report Managed Care
Behind the Bill
Funding Package Extends Medicare Telehealth, Enacts PBM Reforms, and Updates Hospital Oversight
02/05/2026
Juliet Gallagher
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President Donald Trump signed a broad government funding package that includes multi-year extensions for Medicare teleath and hospital-at-home programs, new oversight requirements for pharmacy benefit managers (PBMs), and...
On February 3, 2026, President...
02/05/2026
First Report Managed Care
Behind the Bill
The Senate’s $3 Trillion Deal. Tax Relief Now, Medicaid Coverage Loss Later?
07/02/2025
Katie Hayes, MJ
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After weeks of behind-the-scenes wrangling and last-minute amendments, lawmakers have passed a sprawling tax-and-spending megabill that makes good on a long-standing Republican goal: making the 2017 Trump tax cuts...
The Senate has done it. After...
07/02/2025
First Report Managed Care
Behind the Bill
When a Cap Isn’t Just a Cap: How a Provider Tax Proposal Could Reshape Medicaid Financing
06/25/2025
Katie Hayes, MJ
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most consequential policies are often buried in the fine print. One such detail in the Senate Finance Committee’s latest tax and spending proposal would gradually cap provider taxes—a core funding tool states use to pull in...
In Washington, the most...
06/25/2025
First Report Managed Care
Behind the Bill
Rewriting the Safety Net? Inside the Senate’s Changes to Medicaid and the ACA
06/18/2025
Katie Hayes, MJ
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve been following the progress of the One Big Beautiful Bill Act (OBBBA), which started in the House with sweeping tax reforms and some eye-catching health care proposals. Now, the Senate has released its (highly...
Over the past few weeks, I’ve...
06/18/2025
First Report Managed Care
Behind the Bill
How States Might Respond to the One Big Beautiful Bill Act
06/11/2025
Katie Hayes, MJ
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill Act (OBBBA) still in the hands of the Senate, much of the national conversation has centered on what this legislation would do to federal coverage programs. But regardless of how the federal process unfolds,...
With the One Big Beautiful Bill...
06/11/2025
First Report Managed Care
Behind the Bill
Is the Affordable Care Act on the Chopping Block? What the One Big Beautiful Bill Act Tells Us.
06/04/2025
Katie Hayes, MJ
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of headline-grabbing debate over Medicaid work requirements, and the “One Big Beautiful Bill Act” remains in the Senate as they deliberate over several health care provisions. While the Medicaid provisions sparked most of the...
It’s been weeks of...
06/04/2025
First Report Managed Care
Behind the Bill
From House to Senate: The Journey of Cutting Medicaid
05/28/2025
Katie Hayes, MJ
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of Representatives narrowly passed the One Big Beautiful Bill Act (HR 1, 119th Congress) by a single vote, sending the sweeping tax and spending reconciliation package, backed by President Trump, to the Senate. With its...
Last week, the House of...
05/28/2025
First Report Managed Care
Behind the Bill
Eligibility, Paperwork, and Penalties: The Not-So-Hidden Costs of Medicaid ‘Reform’
05/21/2025
Katie Hayes, MJ
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week in health policy—a phrase that’s quickly becoming routine. This time, House Republicans advanced a sweeping budget reconciliation bill, designed to implement elements of the March budget resolution, with a...
It’s been another eventful week...
05/21/2025
First Report Managed Care
Behind the Bill
A Busy Week in Drug Pricing Policy: Aligning US Drug Prices With Global Standards?
05/14/2025
Katie Hayes, MJ
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for drug pricing policy. While I’d love to dig into the details of both President Trump’s latest executive order and the newest Republican bill that would cut Medicaid spending, we don’t have the time—and this isn’t...
It’s been a busy few days for...
05/14/2025
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use